secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001558370-24-000184
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path completes first dose cohort in Phase 1 trial of BP1002 for lymphoma/CLL
--------------------------------------------------------------------------------

- BP1002, a liposomal Bcl-2 antisense, advanced to next dose cohort (40 mg/m²) after completing 20 mg/m² cohort safely.
- Trial targets refractory/relapsed lymphoma and CLL patients, including those who failed venetoclax-based therapy.
- Phase 1 uses 3+3 design; six evaluable patients per cohort; enrollment open for second cohort.
- BP1002 targets Bcl-2 mRNA, potentially overcoming BH3 domain mutations causing venetoclax resistance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024000184/0001558370-24-000184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024000184/bpth-20240110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer